The case in front of me: ecnoglutide · 2–8 °C.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What is the correct sequence, and where is the step that people usually skip?
Whatever the refrigerated figure is, divide it by about 1. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. So a preparation with a twenty-eight day refrigerated figure has roughly 28 days at 2–8 °C on the same assumption — an order-of-magnitude answer, not a shelf life, and it says nothing about sterility, which has its own clock. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.
Start with the sequence, because which pathways are available depends on which residues are present.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Sequence determines which pathways apply, so general statements are general.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Cold, dry, dark, still. Those four words cover most of the mitigation.
This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
At dilute concentrations, suspect adsorption before you suspect chemistry.
edited 25 May 2026 by halvard_ness — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.